Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch & LombBLCO +2.01%77 Receivables Turnover is 1.07 as of Mar. 2026. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.66 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Bausch & Lomb ranks worse than 65.02% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bausch & Lomb's Revenue for the
three
months ended in Mar. 2026 was $1,244 Mil. Bausch & Lomb's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1,164 Mil.
Hence, Bausch & Lomb's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.07.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bausch & Lomb Receivables Turnover Related Terms
Bausch & Lomb Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLCO vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a Receivables Turnover of 1.07 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bausch & Lomb and its competitors. According to the industry distribution chart, Bausch & Lomb ranks #528 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 65%.
Is Bausch & Lomb's Receivables Turnover too high?
Bausch & Lomb's current Receivables Turnover is 1.07. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Bausch & Lomb's value of 1.07 is 80.6% below this industry median. Based on the distribution chart, Bausch & Lomb ranks #528 out of 812 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #528 out of 812 companies for Receivables Turnover. This places Bausch & Lomb in the lower half of its industry. The industry median Receivables Turnover is 5.51. Bausch & Lomb's value of 1.07 is 80.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current Receivables Turnover of 1.07 is 80.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current Receivables Turnover is 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.66, compared to a current price of $16.28 — trading 12.8% below its estimated fair value. The current Receivables Turnover is 1.07 and 80.6% below the Medical Devices & Instruments industry median of 5.51. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Receivables Turnover is 1.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.28 is trading 12.8% below its estimated GF Value™ of $18.66.
GuruFocus considers Bausch & Lomb to be Modestly Undervalued.
Key valuation signals for BLCO:
Receivables Turnover: 1.07
GF Value™: $18.66 vs. price of $16.28 (12.8% below fair value)
Industry Position: 80.6% below the Medical Devices & Instruments median (#528 of 812)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
